Cytokinetics/CYTK

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Cytokinetics

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Ticker

CYTK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

423

Cytokinetics Metrics

BasicAdvanced
$6.4B
Market cap
-
P/E ratio
-$5.40
EPS
0.74
Beta
-
Dividend rate
$6.4B
0.74
7.188
6.966
-183.049
-190.559
-8.06%
-36.66%
169.74%
1,435.53
-14.53
-14.53
-12.75
-96.17%
15.83%
-59.98%
39.28%

What the Analysts think about Cytokinetics

Analyst Ratings

Majority rating from 18 analysts.
Buy

Cytokinetics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-16,950.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$800K
-50.00%
Net income
-$136M
-0.88%
Profit margin
-16,950.00%
98.25%

Cytokinetics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 16.47%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.34
-$1.35
-$1.38
-$1.33
-
Expected
-$1.15
-$0.74
-$0.97
-$1.14
-$1.08
Surprise
16.93%
81.86%
42.18%
16.47%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cytokinetics stock?

Cytokinetics (CYTK) has a market cap of $6.4B as of July 04, 2024.

What is the P/E ratio for Cytokinetics stock?

The price to earnings (P/E) ratio for Cytokinetics (CYTK) stock is 0 as of July 04, 2024.

Does Cytokinetics stock pay dividends?

No, Cytokinetics (CYTK) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Cytokinetics dividend payment date?

Cytokinetics (CYTK) stock does not pay dividends to its shareholders.

What is the beta indicator for Cytokinetics?

Cytokinetics (CYTK) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Cytokinetics stock

Buy or sell Cytokinetics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing